Arnatar Secures Over $50 Million in Series A Funding with FarReach Capital as Exclusive Financial Advisor

VCBeat learned第一时间 that Arnatar, a biotech company based in San Diego, USA, recently announced the completion of its Series A financing round, raising over 50 million US dollars. This round of financing was jointly completed by FIL Capital Management (Hong Kong) Limited, 3E Bioventures, Zhuhai Huajin Capital Co., Ltd., Gaorong Ventures, Ji Feng Capital, Shanghai New Alliance Investment Management Ltd., Yi Jing Capital, Legendstar Capital, Ariose Capital Management Limited, and Chuanhua Capital. Start Point Advisors served as the exclusive financial advisor for this round of financing. Previously, Arnatar had completed a seed financing round of nearly 100 million RMB, with investment from Apricot Capital, which focuses on investments in the life sciences field.

Arnatar Therapeutics, officially operational in 2022, was founded by a world-class team of scientists in the field of nucleic acid drugs. The company has established a breakthrough nucleic acid drug platform with independent intellectual property rights and continues to explore novel mechanisms of nucleic acid-based drugs, covering multiple therapeutic areas. The proceeds from this fundraising will mainly be used to accelerate the in-depth development of the company's drug pipeline, rapidly advance clinical trials, and support the operational establishment of its China-based entity.